Page 3 - Alimera Sciences News Today

StockNews.com started coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research report released on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reiterated a buy rating and issued a $5.00 target price on shares of Alimera Sciences in a report on Monday, August 14th. […]

StockNews.com started coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research note issued to investors on Wednesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reissued a buy rating and set a $5.00 price objective on shares of Alimera Sciences in a research report […]

StockNews.com began coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research report report published on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reissued a buy rating and issued a $5.00 price objective on shares of Alimera Sciences in a research note on […]

StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research report released on Saturday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright restated a buy rating and set a $5.00 price objective on shares of Alimera Sciences in a research report on Monday, August […]

Investment Analysts’ new coverage for Saturday, November 18th: StockNews.com assumed coverage on shares of Airgain (NASDAQ:AIRG). They issued a hold rating on the stock. StockNews.com assumed coverage on shares of Great Ajax (NYSE:AJX). StockNews.com issued a sell rating on the stock. StockNews.com began coverage on shares of Alimera Sciences (NASDAQ:ALIM). The firm issued a hold […]

StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a report published on Friday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reaffirmed a buy rating and set a $5.00 price target on shares of Alimera Sciences in a report on Monday, August 14th. […]

ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be...

– Positive masked safety data update for EYP-1901 in ongoing PAVIA and DAVIO 2 Phase 2 clinical trials as of October 1, 2023 with no drug related ...

31.10.2023 - ATLANTA, Oct. 31, 2023 (GLOBE NEWSWIRE) - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining ...

StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research report sent to investors on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reiterated a buy rating and set a $5.00 target price on shares of Alimera Sciences in a research report on […]